Our Technology

Methylation of the promoter of lymphocyte antigen 75 (LY75) gene is a strong marker that predicts poor clinical outcome in an independent melanoma series.

Our methylation-specific PCR method for LY75 will allow clinicians to distinguish between melanoma patients who are at LOW RISK versus those who are at HIGH RISK of developing metastatic disease. By determining a patient’s disease risk through a simple test performed by pathologists, a different course of treatment (either more or less intensive) can be chosen.